STOCKS TELEGRAPH

Tag: Soligenix Inc.

  • Soligenix (SNGX) Stock Soars Following Promising Trial Results

    Soligenix (SNGX) Stock Soars Following Promising Trial Results

    Following the release of positive trial data, shares of Soligenix, Inc. (NASDAQ: SNGX) saw a significant increase in value. SNGX’s stock was up 95.20% at $2.44 as of the most recent trading. The spike comes after the company revealed that the major effectiveness goals of its Phase 2a proof-of-concept study for SGX945 (dusquetide) in treating Behçet’s disease were met.

    Phase 2a Research Shows Efficacy on Par with Authorized Therapy

    The Phase 3 study of apremilast (Otezla), which supports its marketing approval for oral ulcers in Behçet’s disease, was closely modeled by the Phase 2a open-label experiment. The results of SGX945 were compared to the apremilast and placebo groups of that Phase 3 trial.

    Over the course of four weeks, SGX945 showed improvements in oral pain and ulcer count that were equivalent to those seen with apremilast. Interestingly, effectiveness continued through Weeks 5–8, almost matching continuous apremilast therapy throughout the same time frame, even though SGX945 medication ended at Week 4.

    Sustained Benefits Beyond Treatment Period

    Using the same primary endpoint—area under the curve (AUC) for mean ulcer count over time—SGX945 achieved a 40% improvement versus placebo, compared to 37% for apremilast. At Week 8, four weeks post-treatment, SGX945 maintained a 32% improvement, while apremilast, administered through Week 12, recorded a 41% improvement.

    Seven of eight patients reported symptom relief, including shorter ulcer duration, fewer occurrences, and reduced pain. A skin ulcer in one patient, typically difficult to treat, resolved during the study. SGX945 was well tolerated, with no treatment-related adverse events reported.

    Future Development and Market Potential

    Soligenix plans to reformulate SGX945 for home-based administration via subcutaneous injection, potentially supporting chronic or maintenance use. SNGX is to progress the development of dusquetide for Behçet’s Disease and other inflammatory illnesses linked to the innate immune system.

    Behçet’s disease is a major unmet medical need, with an estimated 18,000 people in the United States, 50,000 in Europe, 350,000 in Turkey, and up to 1 million worldwide. SGX945 may become a competitive option to existing treatments given the effectiveness, longevity, and tolerability seen, especially for individuals with severe or chronic ulcers.

  • What Do The SNGX Stock Declines On In Premarket?

    As of today’s premarket session, shares of Soligenix Inc. (SNGX) have fallen by -9.16% to $1.19. Soligenix stock added 25.96% to finish the last trading session at $1.31. In the last five days, SNGX stock shares declined 13.93%, but over the last month, they gained 21.30%. Over the last three months, SNGX stock price has fallen by 17.09 percent, and this year so far it has fallen by 31.05 percent. In premarket trading, SNGX stock is falling as investors are seen to be taking profits off of gains made in yesterday’s trading.

    SNGX rose in regular session for what reason?

    As a biopharmaceutical company, Soligenix focuses on the development and marketing of products for the treatment of rare diseases where there is a medical need. The Specialized BioMarketing business segment of SNGX is developing and exploring the potential commercialization of HyBryte, which is a novel photodynamic therapy utilizing safe visible light to treat cutaneous T-cell lymphomas (CTCL). The Phase 3 study for this product candidate has been completed successfully, and SNGX is seeking approval to advance commercialization activities.

    Yesterday, PCG Digital published an interview with Dr. Ellen Kim, Lead Principal Investigator for Soligenix. At the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting, she presented key details of the Phase 3 FLASH study for Soligenix in CTCL that recently showed significant efficacy and safety data for HyBryte. After the meeting, Dr. Kim was interviewed concerning the HyBryte data and current CTCL treatment options.

    At the USCLC Annual Meeting scheduled for June 26, 2021, Dr. Kim presented critical details about efficacy and safety profile of Soligenix’s HyBryte, demonstrated in the FLASH study.

    • HyBryte was studied in detail at SNGX, which showed it to be safe and effective in the vast majority of CTCL patients.
    • As part of the study, SNGX presented a comparison between the study data and current treatment options.
    • SNGX’s FLASH trial has recruited 169 patients, making it the largest multicenter, randomized, double-blind, placebo-controlled study in CTCL to date.
    • SNGX developed HyBryte so that it would be a safer alternative to currently available therapies, which all have significant and sometimes fatal side effects.
    • There is no suitable front-line therapy at present, and the currently approved treatments only exist after previous treatments have failed.

    What it means for SNGX?

    In a landscape with many competitive players, Soligenix (SNGX) may have a greater opportunity in CTCL treatment, since HyBryte might represent the most efficacious treatment available that is also as safe as possible. To date, SNGX has found no evidence of any potential safety issues in that product due to its lack of systemic absorption, nonmutagenic compound, and carcinogenic light source.

  • 18 Biotech Stocks That Are Great Options To Invest In

    18 Biotech Stocks That Are Great Options To Invest In

    The biotech industry is considered to be an attractive industry for the investor. This industry is continuously adopting new technological advancements. As time passes by every aspect of daily existence experience changes because of new technological breakthroughs and advancement in knowledge. Technology plays an important role in changing the lifestyle of humans. This technology also plays a very important role in the biotech industry.

    This technology has historically grown quickly. The biotech industry is striving to develop a treatment for complex diseases. It is anticipated that in 2021, one of the continuing trends in biotech is the continued improvement and development of drug research. The new technology help researchers to improve and assess diagnosis and treatment using medications.

    Check out the top 18 biotech companies you should add to your portfolio:

    BioLineRx Ltd. (NASDAQ: BLRX)

    BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 33.78% at $1.98 at the time of writing on Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks, though shares have since pulled back to $1.98. BLRX market cap has remained high, hitting $39.57M at the time of writing. BioLineRx Ltd. (BLRX) has earlier announced the promising results from the ongoing GENESIS Phase III trial motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    Miragen Therapeutics Inc. (NASDAQ: MGEN)

    Miragen Therapeutics Inc. (NASDAQ: MGEN) last closed at $1.31, in a 52-week range of $0.31 to $2.27. Miragen Therapeutics Inc. (MGEN) has earlier acquired  Viridian Therapeutics, Inc. It has traded up 321.22% and traded down -42.29% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.80 and a quick ratio of 4.80. This company has a market capitalization of $79.29 million at the time of writing.

    Equillium Inc. (NASDAQ: EQ)

    Equillium Inc. (NASDAQ: EQ) stock soar by 5.83% to $6.35. The most recent rating by H.C. Wainwright, on July 14, 2020, is at a Buy. Previously, Equillium Inc. (EQ) has revealed that it has received a ‘Study May Proceed letter’ from the U.S. Food and Drug Administration (FDA) to commence a Phase 3 clinical trial, titled  EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP)

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP) shares headed falling, lower as much as -3.24%. The most recent rating by Maxim Group, on June 26, 2019, is at a Buy. Titan Pharmaceuticals Inc. (TTNP) revealed the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering comprised of one share of common stock and one warrant to purchase one share of common stock.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) rose 2.34% after gaining more than $0.06 on Friday. Trevena Inc. (TRVN) has disclosed that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA). Looking at its liquidity, it has a current ratio of 16.20 and a quick ratio of 16.20. This company has a market capitalization of $381.29 million at the time of writing.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) last closed at $6.94, in a 52-week range of $1.45 to $19.39. Sorrento Therapeutics Inc. (SRNE) has earlier announced preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) shares headed falling, lower as much as -1.69%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) has earlier appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) fall -6.10% after losing more than -$0.64 on Friday. Inovio Pharmaceuticals Inc. (INO) announced that it is scheduled to release its third-quarter financial results of 2020 on November 9, 2020.  This company has a market capitalization of $1.76 billion at the time of writing.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) last closed at $4.92, in a 52-week range of $0.27 to $17.49. A class action has started on behalf of certain shareholders in Vaxart, Inc. It has traded up 1749.62% and traded down -71.87% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.00 and a quick ratio of 4.00. This company has a market capitalization of $580.22 million at the time of writing.

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT)

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT) stock drop by -41.64% to $2.13. The most recent rating by Cantor Fitzgerald, on April 17, 2020, is at an Overweight. Axovant Gene Therapies Ltd. (AXGT) has earlier announced program updates on Friday, October 30, 2020, at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) shares headed falling, lower as much as -2.20%. The most recent rating by Needham, on November 14, 2019, is at a Buy. Akebia Therapeutics Inc. (AKBA) earlier revealed that it is scheduled to announce its financial results for the third quarter ended September 30, 2020, on November 5, 2020, before the opening of the market.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) fall -5.35% after losing more than -$3.81 on Friday. Moderna Inc. (MRNA) earlier revealed that it has been recognized as one of the global biopharmaceutical industry’s top employers in Science and ScienceCareers’ 2020 Top Employers Survey for the sixth consecutive year.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 3.45% to $1.20. The most recent rating by B. Riley Securities, on October 14, 2020, is at a Buy. Heat Biologics Inc. (HTBX) share price went from a low point around $0.19 to briefly over $4.30 in the past 52 weeks, though shares have since pulled back to $1.20. HTBX market cap has remained high, hitting $172.30 Million at the time of writing.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.26, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) revealed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock drop by -4.27% to $4.93. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) is scheduled to release its third-quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares headed rising, higher as much as 2.41%. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight. BioCryst Pharmaceuticals Inc. (BCRX) revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

    Soligenix Inc. (NASDAQ: SNGX)

    Soligenix Inc. (NASDAQ: SNGX) rose 0.59% after gaining more than $0.01 on Friday. Soligenix Inc. (SNGX) has disclosed that continued optional treatment with SGX301 across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH study.

    Scholar Rock Holding Corporation (SRRK)

    Scholar Rock Holding Corporation (SRRK) last closed at $38.90, in a 52-week range of $6.95 to $46.50. Analysts have a consensus price target of $30.00. Scholar Rock Holding Corporation (SRRK) announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.